CLINICAL RESEARCH COOPERATIVE

临床研究合作社

基本信息

  • 批准号:
    6378981
  • 负责人:
  • 金额:
    $ 210万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1999
  • 资助国家:
    美国
  • 起止时间:
    1999-09-30 至 2004-08-31
  • 项目状态:
    已结题

项目摘要

As clinical trial researchers and treatment providers since 1974, we believe that the major need within the field of addiction is for a working partnership between leaders in the research and in the treatment provider community. This partnership should elevate the standards of both treatment and research in this field. To this end we have Philadelphia metropolitan statistical area as part of the NIDA Clinical Trials Network. We have recruited and cultivated collaborative relationships with seven of the very best organizations representing 60 treatment programs from this region; those with distinguished records in training and a record of community leadership. All the programs that have joined our cooperative have participated in multiple research projects over the past ten years and each program has empirical evidence of high quality treatment through prior, independent evaluations. Thus, our Cooperative has been constructed as a consortium of excellence in treatment, research and education. In this proposal we provide evidence that our Cooperative can contribute to the broader goals of changing the way addiction treatment is taught, practiced and perceived. Specifically, we will: * Direct at least one research study each year from one of three areas: 1. Controlled clinical trials of medications. 2. Controlled clinical trials of behavioral and psychosocial treatments. 3. Health Services and Practice studies of treatment access, financing and organization. * Participate in at least two additional research studies each year from the three areas. * Develop two important training and technology transfer skills. 1. Train new and existing professionals in the delivery, management and monitoring of the improved treatment methods. 2. Implement into standard practice within our Cooperative at least two medications and at least two behavioral therapies-by the end of the fifth year we will also have implemented at least one medication and one behavioral therapy into standard practice in programs outside the cooperative. * Represent the field of addiction to the world of providers, payers and policy makers, supporting medications and treatments that have been validated by the CTN.
自1974年以来,作为临床试验研究人员和治疗提供者,我们认为成瘾领域的主要需求是研究和治疗提供者社区的领导者之间的工作伙伴关系。这种伙伴关系应提高这一领域的治疗和研究标准。为此,我们将费城大都市统计区作为NIDA临床试验网络的一部分。我们已经招募并培养了来自该地区60个治疗项目的七个最好的组织的合作关系;那些在培训和社区领导记录方面有杰出记录的组织。在过去的十年里,所有加入我们合作的项目都参与了多个研究项目,每个项目都通过事先的独立评估获得了高质量治疗的经验证据。因此,我们的合作社已建成一个卓越的治疗,研究和教育的财团。在这项提案中,我们提供的证据表明,我们的合作社可以为改变成瘾治疗的教学,实践和感知方式的更广泛目标做出贡献。具体而言,我们将:* 每年至少指导一项研究,研究范围包括以下三个方面:1.药物临床对照试验。2.行为和心理社会治疗的对照临床试验。3.卫生服务和治疗的获得,融资和组织的实践研究。* 每年至少参加两次来自这三个领域的额外研究。* 发展两项重要的培训和技术转让技能。1.培训新的和现有的专业人员提供、管理和监测改进的治疗方法。2.在我们的合作社内实施至少两种药物和至少两种行为疗法的标准实践-到第五年年底,我们还将在合作社外的项目中实施至少一种药物和一种行为疗法的标准实践。* 代表成瘾领域的世界提供者,付款人和政策制定者,支持药物和治疗已被CTN验证。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

GEORGE Edward WOODY其他文献

GEORGE Edward WOODY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('GEORGE Edward WOODY', 18)}}的其他基金

Opioid Relaps & HIV Risk: 48 vs. 24 Weeks of ER Injectable Naltrexone
阿片类药物复发
  • 批准号:
    8717625
  • 财政年份:
    2012
  • 资助金额:
    $ 210万
  • 项目类别:
Opioid Relaps & HIV Risk: 48 vs. 24 Weeks of ER Injectable Naltrexone
阿片类药物复发
  • 批准号:
    8519398
  • 财政年份:
    2012
  • 资助金额:
    $ 210万
  • 项目类别:
Opioid Relaps & HIV Risk: 48 vs. 24 Weeks of ER Injectable Naltrexone
阿片类药物复发
  • 批准号:
    9116813
  • 财政年份:
    2012
  • 资助金额:
    $ 210万
  • 项目类别:
Opioid Relaps & HIV Risk: 48 vs. 24 Weeks of ER Injectable Naltrexone
阿片类药物复发
  • 批准号:
    8310620
  • 财政年份:
    2012
  • 资助金额:
    $ 210万
  • 项目类别:
Adherence to HIV Therapy in Heroin Addicts: Oral vs Extended Release Naltrexone
海洛因成瘾者对艾滋病毒治疗的依从性:口服纳曲酮与缓释纳曲酮
  • 批准号:
    7756239
  • 财政年份:
    2009
  • 资助金额:
    $ 210万
  • 项目类别:
Suboxone and Methadone for HIV Risk Reduction in Subutex Injectors
Suboxone 和美沙酮可降低 Subutex 注射器中的 HIV 风险
  • 批准号:
    7684519
  • 财政年份:
    2009
  • 资助金额:
    $ 210万
  • 项目类别:
Adherence to HIV Therapy in Heroin Addicts: Oral vs Extended Release Naltrexone
海洛因成瘾者对艾滋病毒治疗的依从性:口服纳曲酮与缓释纳曲酮
  • 批准号:
    8143927
  • 财政年份:
    2009
  • 资助金额:
    $ 210万
  • 项目类别:
Adherence to HIV Therapy in Heroin Addicts: Oral vs Extended Release Naltrexone
海洛因成瘾者对艾滋病毒治疗的依从性:口服纳曲酮与缓释纳曲酮
  • 批准号:
    8092869
  • 财政年份:
    2009
  • 资助金额:
    $ 210万
  • 项目类别:
Adherence to HIV Therapy in Heroin Addicts: Oral vs Extended Release Naltrexone
海洛因成瘾者对艾滋病毒治疗的依从性:口服纳曲酮与缓释纳曲酮
  • 批准号:
    8298404
  • 财政年份:
    2009
  • 资助金额:
    $ 210万
  • 项目类别:
Adherence to HIV Therapy in Heroin Addicts: Oral vs Extended Release Naltrexone
海洛因成瘾者对艾滋病毒治疗的依从性:口服纳曲酮与缓释纳曲酮
  • 批准号:
    8288300
  • 财政年份:
    2009
  • 资助金额:
    $ 210万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了